Prediction of early recurrencies of uterine body cancer based on monitoring of serum biological markers

Abstract

The aim of this work was to optimize the prognosis of early recurrences of uterine cancer by searching for informative laboratory biomarkers. The study included 343 patients with I-IV stages FIGO endometrial adenocarcinoma the ages of 53 and 76 years. In patients before surgery, as well as 3 and 6 months after the end of primary treatment, the concentration of oncological markers CA-125, HE4, DJ-1, DKK-1 was determined in blood serum by ELISA and electrochemiluminescence immunoassay. We analyzed the predictive informativeness of monitoring markers to assess the risk of early recurrences of cancer within two years after surgery. In patients with uterine cancer with the stage of the disease and the degree of tumor differentiation in the blood serum, the concentration of DJ-1 is changed. With myometrial invasion of more than 50%, increased serum levels of three markers - CA-125, HE4, and DJ-1. Depending on the risk of disease recurrence, the assessment of which was determined by intraoperative and histological characteristics, a difference was revealed in the content of HE4 and DJ-1 markers in the blood. It was found that the risk of early recurrence of uterine cancer increased (p<0,05) when the concentration of CA-125 exceeded the level of 29,3 U/ml, HE4 was above 79,3 pmol/l, DJ-1 was above 90,0 ng/ml and DKK-1 above 47,3 pg/ml 6 months after the end of primary treatment. The highest predictive information value was found for monitoring DJ-1 and HE4 in blood serum, which indicates that they are promising for use in continuous monitoring of the course of cancer.

Prognostic significance of determining the activity and level of immune subunits of proteasomes in endometrial cancer

“…Как правило, РЭ диагностируется на ранних стадиях, что позволяет достигать хороших результатов лечения и высокую общую пятилетнюю выживаемость (75-83 %). Показатель одногодичной летальности в России по данному заболеванию составил 8,5 % в 2020 г., однако велика частота развития рецидивов, что определяет актуальность поиска дополнительных факторов неблагоприятного прогноза при раке тела матки [1,2].…”

“…На роль прогностических факторов РЭ могут претендовать многие биологически активные молекулы, участвующие в патогенезе этого заболевания. В частности, в качестве критериев прогноза течения заболевания у пациенток с раком тела матки было предложено исследование уровня онкологических маркеров CA-125, HE4, DJ-1, DKK-1 [2]. Предпринимаются попытки разработать молекулярную классификацию РЭ, которая может быть востребована для лечения новообразований [4].…”